Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/ll Clinical Study to Evaluate Safety and Dosing of Humanised Monoclonal Antibody CA9hu-1 to Human Carbonic Anhydrase IX in Patients With Advanced Solid Tumours

NCT05698238 is registered in ClinicalTrials.gov with Mabpro, a.s. as lead sponsor.

NCT NCT05698238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05698238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/ll Clinical Study to Evaluate Safety and Dosing of Humanised Monoclonal Antibody CA9hu-1 to Human Carbonic Anhydrase IX in Patients With Advanced Solid Tumours
Lead sponsor
Mabpro, a.s.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 31, 2024
Completion date
January 31, 2027
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma metastatic, head and neck cancer, mesothelioma, malignant, non-small-cell lung carcinoma, tnbc - triple-negative breast cancer